Raimondi, A.Morano, F.Trarbach, T.Karthaus, M.Lonardi, S.Fruehauf, S.Cremolini, C.Graeven, U.Bittoni, A.Mueller, L.Bianchi, A. SartoreAranda, E.Boige, V.Stintzing, S.Di Bartolomeo, M.Koenig, A.Pietrantonio, F.Modest, D.2023-05-032023-05-032022-06-01Raimondi A, Morano F, Trarbach T, Karthaus M, Lonardi S, Fruehauf S, et al. SO-21 Optimal maintenance treatment strategy following an anti-EGFR-based first-line induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of clinical trials. Annals Of Oncology [Internet]. 1 de junio de 2022;33:S3660923-7534http://hdl.handle.net/10668/21914Background: In metastatic colorectal cancer (mCRC), after a first-line induction with doublet/triplet chemotherapy plus bevacizumab, fluoropyrimidine+bevacizumab is the recommended maintenance option. The combination of anti-EGFR agents and chemotherapy is a guideline-endorsed first-line option for RAS/BRAF wild-type (wt) mCRC patients, but the optimal maintenance schedule has not been defined, yet. The Valentino trial showed that, after 4-month FOLFOX+panitumumab induction, singleagent panitumumab induced inferior progression-free survival (PFS) than FUFA+panitumumab, though slightly reducing toxicity. The Panama study demonstrated that, after 3-month FOLFOX+panitumumab induction, FUFA+panitumumab induced a significantly superior PFS than FUFA alone.enPanitumumabBevacizumabProto-oncogene proteins B-rafHumansProgression-free survivalColorectal neoplasmsColonic neoplasmsRectal neoplasmsconference outputopen accessHumanosNeoplasias colorrectalesNeoplasias del colonNeoplasias del rectoSupervivencia sin progresión10.1016/j.annonc.2022.04.4201569-8041http://www.annalsofoncology.org/article/S0923753422011103/pdf823826500341